glp-1 lawsuits Ozempic® Lawsuit If you are taking GLP-1’s,
Description
Clinical data sources All clinical trial data cited in this report is drawn from peer-reviewed publications in The New England Journal of Medicine and The Lancet, and investor disclosures from Novo Nordisk and Eli Lilly
The Parenteral segment dominated the market with a share of 67.45% in 2025 due to the widespread availability and clinical success of injectable GLP-1 therapies
Thats up to 75% less for the same active ingredient
Nonetheless, gastrointestinal adverse symptoms (e.g., nausea, vomiting) persist often, and long-term safety data are still being examined
Schofield, M
